Pricing Log in Create free account
Friday 6 November 2026 Export LIVN’s income statement to Excel — free account

LivaNova PLC

LIVN Healthcare Medical Devices

LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.

Revenue
+9.88%
EPS
+27.4%
Free cash flow
−31.0%
Total debt
−31.2%

Quarter to September 2026, against a year earlier

91.25 0.11 +0.12%
Market cap
$5.0B
P/E
25.6×
Fwd P/E
19.8×
Dividend yield
—
F-score
4/9
Altman Z
1.74
Beneish M
−3.30
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 1.03
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — 1 1 — 2 2 — —
Insider Ownership 0.42%

Capital & Financial Ratios $m

Size
Market Cap 5,020.00
Revenue ttm 1,506.87
Net income ttm 196.11
Free cash flow ttm 136.35
Net debt Q (264.40)
Valuation
P/E 25.58
Forward P/E 19.80
Price / sales 3.35
Forward P/S Powerpack
Price / FCF 37.98
Price / book 3.81
Financial health
Current ratio Q 1.74 (at or above 1.5: strong)
Debt / equity Q 0.22 (at or below 0.5: strong)
Interest coverage Q 3.55
Growth
Revenue growth Q +9.88% (above 0%: growing)
Operating income growth Q −47.42% (below 0%: shrinking)
EPS, this year +13.49%
EPS, next year A +6.62%
Revenue, next year A +9.65%
EPS, past 5 yrs —
EPS, next 5 yrs A +10.02%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.2×, against a ten-year median of 3.0×; over the ten years it ranged from 1.5× in 2025 to 5.8× in 2018.
P/S against its own 10 years 61.09%
10-year low 10-year high
P/B against its own 10 years 97.54%
10-year low 10-year high
EV/Sales against its own 10 years 51.85%
10-year low 10-year high
EV/FCF against its own 10 years 28.20%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 578 724 636 564
Receivables 215 193 216 236
Inventory 148 148 165 178
Other — — — —
988 1,127 1,102 564
2023 2024 2025 Q'26
Payables 81 70 97 107
ST’ Debt 18 78 31 4
Other 11 13 459 384
335 392 808 324

Compound Annual Growth %

10y 5y 3y
Sales 16.89% 8.24% 10.75%
Cash Flow 12.31% 0.00% 53.79%
Earnings 0.00% 0.00% 0.00%
Book Value (4.03%) 1.58% (0.21%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 1.03 Actual 1.23

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.80 0.86 Beat by 0.06
Q1 FY26 0.85 0.98 Beat by 0.13
Q2 FY26 1.08 1.26 Beat by 0.18
Q3 FY26 1.03 1.23 Beat by 0.20
Q4 FY26 1.07 — Reports 24 February 2027

EPS $

Mar Jun Sep Dec Year
’26 0.40 1.93 0.60 — —
’25 (6.01) 0.50 0.49 0.56 (4.45)
’24 (0.78) 0.30 0.60 1.02 1.16
’23 0.14 0.02 (0.14) 0.30 0.32
’22 0.06 0.30 (2.01) 0.03 (1.61)
’21 (0.61) (1.13) (0.82) (0.10) (2.68)
’20 0.77 (1.81) (0.30) (5.75) (7.10)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 362 391 393 — —
’25 317 353 358 361 1,388
’24 295 319 318 322 1,253
’23 263 294 286 310 1,154
’22 240 254 253 275 1,022
’21 248 264 253 270 1,035
’20 242 182 240 270 934
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 15 67 74 — —
’25 24 63 85 82 254
’24 10 43 51 79 183
’23 21 (18) 18 54 75
’22 26 (10) 36 19 70
’21 19 26 24 33 103
’20 (106) (19) 9 37 (79)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 1 35 43 — —
’25 13 48 62 57 181
’24 4 31 33 68 136
’23 13 (24) 9 42 41
’22 21 (16) 30 10 43
’21 11 19 21 26 77
’20 (114) (29) (2) 30 (114)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 965 1,012 1,107 1,084 934 1,035 1,022 1,154 1,253 1,388 1,507 +4.1% 1,522 1,630 1,745 +7.9%
Gross margin, % 57.99 64.39 66.39 66.76 63.66 68.19 69.21 65.52 68.09 67.71 67.84 +9.7 pt
EBT 26 121 (247) (188) (348) (124) (75) (81) 88 (221) 120 n/m
EBT margin, % 2.66 11.97 (22.35) (17.38) (37.25) (12.02) (7.35) (7.04) 7.05 (15.91) 7.99 (18.6) pt
Net income (63) (25) (189) (158) (349) (136) (86) 18 63 (242) 196 +16.2%
Per share, $
Per share, $ Revenue 19.75 21.02 22.83 22.42 19.23 20.45 19.11 21.39 23.11 25.45 27.35 +2.9%
Earnings (1.29) (0.52) (3.91) (3.21) (7.10) (2.68) (1.61) 0.33 1.17 (4.45) 3.58 +14.7%
Cash flow 1.85 1.90 2.48 (1.89) (1.63) 2.03 1.31 1.39 3.37 4.66 4.32 +10.8%
Capex (0.76) (0.58) (0.49) (0.58) (0.72) (0.50) (0.50) (0.63) (0.87) (1.35) (1.84) +6.6%
Free cash flow 1.08 1.31 1.99 (2.46) (2.36) 1.52 0.81 0.76 2.51 3.31 2.47 +13.2%
Book value 34.93 37.70 31.01 28.62 22.83 25.57 22.58 23.69 24.34 22.00 24.90 (5.0%)
Shares, m 49 48 48 48 49 51 53 54 54 55 55 +1.2%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 157.94 39.92 0.00 25.58 19.8
P/S 2.30 3.80 4.01 3.36 3.44 4.28 2.89 2.36 2.00 2.42 3.35 3.1
P/B 1.30 2.12 2.95 2.64 2.90 3.42 2.44 2.13 1.90 2.80 3.81 2.5
EV/Sales 2.38 3.86 4.12 3.62 3.87 4.31 2.91 2.37 1.93 2.23 3.18 3.2
EV/FCF 50.10 66.85 47.70 (32.92) (30.73) 60.48 74.33 72.48 18.21 17.48 36.00 34.4
Cash, $m
Cash, $m Operating cash flow 90 91 120 (91) (79) 103 70 75 183 254 238 +12.2%
Capex (37) (28) (24) (28) (35) (25) (27) (34) (47) (74) (102) +7.9%
Free cash flow 53 63 97 (119) (114) 77 43 41 136 181 136 +14.6%
Balance, $m
Balance, $m Working capital 463 464 37 37 399 (18) 589 653 735 294 240 (4.9%)
Net debt 83 52 121 277 403 32 26 9 (96) (259) (264) n/m
Shareholders’ equity 1,707 1,815 1,504 1,384 1,109 1,295 1,208 1,278 1,320 1,200 1,372 (3.8%)
Returns, %
Returns, % ROA (2.56) (1.04) (7.50) (6.35) (14.50) (5.90) (3.84) 0.74 2.56 (9.49) 7.44 (6.9) pt
ROIC 1.17 3.23 (9.54) (6.46) (11.32) (0.04) (3.89) (3.33) 6.59 13.24 9.14 +12.1 pt
ROE (3.57) (1.42) (11.41) (10.92) (27.98) (11.30) (6.89) 1.41 4.87 (19.24) 15.50 (15.7) pt
People
People Employees 4,500 4,500 4,000 4,000 4,000 3,000 2,900 2,900 2,900 3,300 — (3.4%)
Revenue/emp, $m 0.21 0.22 0.28 0.27 0.23 0.35 0.35 0.40 0.43 0.42 — +7.8%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

LivaNova PLC vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BIO Bio-Rad Laboratories, Inc. $9.9B 9.7× 44.7× +0.52% (above 0%: growing) n/m +8.07% (above 0%: growing) 50.06% (7.57%) Compare
BRKR Bruker Corporation $8.9B — (loss-making) — (loss-making) +1.57% (above 0%: growing) n/m +278.74% (above 0%: growing) 49.12% (10.41%) Compare
TXG 10x Genomics $7.6B — (loss-making) — (loss-making) −12.65% (below 0%: shrinking) n/m −4.61% (below 0%: shrinking) 74.48% (12.95%) Compare
HAE Haemonetics Corporation $5.7B 54.5× 30.2× +9.30% (above 0%: growing) +25.93% (above 0%: growing) +20.37% (above 0%: growing) 61.75% 21.00% Compare
LIVN LivaNova PLC $5.0B 25.6× 19.8× +9.88% (above 0%: growing) +27.41% (above 0%: growing) −30.95% (below 0%: shrinking) 67.41% 7.22%
ITGR Integer Holdings Corporation $4.3B 42.2× 38.9× −3.86% (below 0%: shrinking) −61.04% (below 0%: shrinking) −65.19% (below 0%: shrinking) 22.59% 6.27% Compare
IRTC iRhythm Holdings, Inc. $4.3B — (loss-making) — (loss-making) +14.88% (above 0%: growing) n/m −157.58% (below 0%: shrinking) 74.23% (14.69%) Compare
AXGN AxoGen, Inc. $2.9B — (loss-making) — (loss-making) +26.22% (above 0%: growing) +163.16% (above 0%: growing) +994.99% (above 0%: growing) 74.81% 1.26% Compare
NEOG Neogen Corporation $2.6B — (loss-making) — (loss-making) +6.50% (above 0%: growing) n/m +135.61% (above 0%: growing) 47.35% (0.81%) Compare
Median of peers $5.0B 42.2× 38.9× +4.04% +25.93% +14.22% 55.91% (4.19%)

All 149 Medical Devices stocks →

LivaNova PLC (LIVN) Latest News

4 Nov

Impact 3 · · Simply Wall St.
Impact 3 · · GuruFocus.com
Impact 3 · · Moby
Impact 3 · · The Motley Fool transcript
Impact 3 · · MarketBeat
Impact 3 · · Zacks
Impact 3 · · Business Wire

28 Oct

Impact 3 · · Zacks

23 Oct

Impact 4 · · Business Wire

21 Oct

Impact 3 · · Business Wire

9 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · Simply Wall St.

24 Sep

Impact 4 · · Insider Monkey

17 Aug

Impact 3 ·

12 Aug

Impact 4 ·
Impact 3 ·
Impact 3 · · The Motley Fool transcript

6 Aug

Impact 4 ·

5 Aug

Impact 4 ·
Impact 4 · · InvestorsHub
Impact 4 ·
Impact 3 · · Moby transcript
Impact 3 · · MarketBeat
Impact 3 ·

17 Jun

Impact 3 ·

16 Jun

Impact 4 ·

9 May

Impact 4 · · Simply Wall St.

7 May

Impact 4 · · The Motley Fool transcript

6 May

Impact 4 · · Moby
Impact 4 · · MarketBeat

LIVN metrics, ten years each

stockrow.com/LIVN · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com